132 related articles for article (PubMed ID: 28293071)
21. Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein.
Manjunathan R; Periyaswami V; Mitra K; Rosita AS; Pandya M; Selvaraj J; Ravi L; Devarajan N; Doble M
BMC Bioinformatics; 2022 May; 23(1):180. PubMed ID: 35578172
[TBL] [Abstract][Full Text] [Related]
22. Exploring the interaction mechanism between potential inhibitor and multi-target Mur enzymes of mycobacterium tuberculosis using molecular docking, molecular dynamics simulation, principal component analysis, free energy landscape, dynamic cross-correlation matrices, vector movements, and binding free energy calculation.
Kumari M; Singh R; Subbarao N
J Biomol Struct Dyn; 2022; 40(24):13497-13526. PubMed ID: 34662260
[TBL] [Abstract][Full Text] [Related]
23. A combination strategy of structure-based virtual screening, MM-GBSA, cross docking, molecular dynamics and metadynamics simulations used to investigate natural compounds as potent and specific inhibitors of tumor linked human carbonic anhydrase IX.
Chahal V; Kakkar R
J Biomol Struct Dyn; 2023; 41(12):5465-5480. PubMed ID: 35735269
[TBL] [Abstract][Full Text] [Related]
24. Flavanones: A potential natural inhibitor of the ATP binding site of PknG of
Swain SP; Gupta S; Das N; Franca TCC; Goncalves ADS; Ramalho TC; Subrahmanya S; Narsaria U; Deb D; Mishra N
J Biomol Struct Dyn; 2022; 40(22):11885-11899. PubMed ID: 34409917
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
Saxena S; Abdullah M; Sriram D; Guruprasad L
J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
[TBL] [Abstract][Full Text] [Related]
26. Uridine monophosphate kinase as potential target for tuberculosis: from target to lead identification.
Arvind A; Jain V; Saravanan P; Mohan CG
Interdiscip Sci; 2013 Dec; 5(4):296-311. PubMed ID: 24402823
[TBL] [Abstract][Full Text] [Related]
27. Discovery of new inhibitors of Mycobacterium tuberculosis EPSP synthase - A computational study.
Dahmer BR; Ethur EM; Timmers LFSM
J Mol Graph Model; 2023 Jun; 121():108404. PubMed ID: 36907015
[TBL] [Abstract][Full Text] [Related]
28. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents.
Sharma K; Tanwar O; Sharma S; Ali S; Alam MM; Zaman MS; Akhter M
Bioorg Chem; 2018 Oct; 80():319-333. PubMed ID: 29986181
[TBL] [Abstract][Full Text] [Related]
29. Identification of Novel Inhibitor of Enoyl-Acyl Carrier Protein Reductase (InhA) Enzyme in
Singh K; Pandey N; Ahmad F; Upadhyay TK; Islam MH; Alshammari N; Saeed M; Al-Keridis LA; Sharma R
Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36009907
[No Abstract] [Full Text] [Related]
30. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase.
Jung IP; Ha NR; Lee SC; Ryoo SW; Yoon MY
Int J Antimicrob Agents; 2016 Sep; 48(3):247-58. PubMed ID: 27451857
[TBL] [Abstract][Full Text] [Related]
31. Identification of potential non-nucleoside MraY inhibitors for tuberculosis chemotherapy using structure-based virtual screening.
Pandey P; Chatterjee S; Berida T; Doerksen RJ; Roy S
J Biomol Struct Dyn; 2022 Jul; 40(11):4832-4849. PubMed ID: 33353500
[TBL] [Abstract][Full Text] [Related]
32. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.
Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK
J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Mycobacterium tuberculosis α-1,4-glucan branching enzyme (GlgB) inhibitors by structure- and ligand-based virtual screening.
Dkhar HK; Gopalsamy A; Loharch S; Kaur A; Bhutani I; Saminathan K; Bhagyaraj E; Chandra V; Swaminathan K; Agrawal P; Parkesh R; Gupta P
J Biol Chem; 2015 Jan; 290(1):76-89. PubMed ID: 25384979
[TBL] [Abstract][Full Text] [Related]
34. Mycobacterium Time-Series Genome Analysis Identifies AAC2' as a Potential Drug Target with Naloxone Showing Potential Bait Drug Synergism.
Niranjan V; Uttarkar A; Murali K; Niranjan S; Gopal J; Kumar J
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234683
[TBL] [Abstract][Full Text] [Related]
35. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
36. Pharmacophore model-based virtual screening, docking, biological evaluation and molecular dynamics simulations for inhibitors discovery against
Naz S; Farooq U; Khan S; Sarwar R; Mabkhot YN; Saeed M; Alsayari A; Muhsinah AB; Ul-Haq Z
J Biomol Struct Dyn; 2021 Feb; 39(2):610-620. PubMed ID: 31937192
[TBL] [Abstract][Full Text] [Related]
37. Structural and energetic understanding of novel natural inhibitors of Mycobacterium tuberculosis malate synthase.
Shukla R; Shukla H; Tripathi T
J Cell Biochem; 2019 Feb; 120(2):2469-2482. PubMed ID: 30206985
[TBL] [Abstract][Full Text] [Related]
38. Molecular docking, molecular dynamics simulations and binding free energy studies of interactions between Mycobacterium tuberculosis Pks13, PknG and bioactive constituents of extremophilic bacteria.
Nyambo K; Tapfuma KI; Adu-Amankwaah F; Julius L; Baatjies L; Niang IS; Smith L; Govender KK; Ngxande M; Watson DJ; Wiesner L; Mavumengwana V
Sci Rep; 2024 Mar; 14(1):6794. PubMed ID: 38514663
[TBL] [Abstract][Full Text] [Related]
39. In silico and in vitro study of Mycobacterium tuberculosis H37Rv uncharacterized protein (RipD): an insight on tuberculosis therapeutics.
Arega AM; Dhal AK; Nayak S; Mahapatra RK
J Mol Model; 2022 May; 28(6):171. PubMed ID: 35624324
[TBL] [Abstract][Full Text] [Related]
40. Structure-based identification of natural compound inhibitor against
Lata S; Akif M
J Biomol Struct Dyn; 2021 Aug; 39(12):4480-4489. PubMed ID: 32567497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
